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We identiﬁed two novel GATA2 mutations in acute myeloid leukemia (AML). One mutation (p.R308P-
GATA2) was a R308P substitution within the zinc ﬁnger (ZF)-1 domain, and the other
(p.A350_N351ins8-GATA2) was an eight-amino-acid insertion between A350 and N351 residues within
the ZF-2 domain. p.R308P-GATA2 did not affect DNA-binding and transcriptional activities, while
p.A350_N351ins8-GATA2 reduced them, and impaired G-CSF-induced granulocytic differentiation of
32D cells. Although p.A350_N351ins8-GATA2 did not show a dominant-negative effect over wild-type
(Wt)–GATA2 by the reporter assay, it might be involved in the pathophysiology of AML by impairing
myeloid differentiation because of little Wt-GATA2 expression in primary AML cells harboring the
p.A350_N351ins8 mutation.
& 2013 Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
GATA transcription factors contribute to the regulation of cell
lineage commitment and differentiation.1 Although hematopoi-
esis is controlled by numerous transcription and signaling factors
with tightly integrated functions, GATA1, GATA2 and GATA3 in
the GATA family are involved in the developmental regulation of
hematopoiesis. In addition to the essential role in normal hema-
topoiesis, recent studies demonstrated that mutation of GATA
genes is involved in the development and progression of leuke-
mia. p.L359V mutation of GATA2 gene was identiﬁed in about 10%
of chronic myeloid leukemia (CML) cases at accelerated phase and
myeloid blast crisis.2 Moreover, recent studies demonstrated that
GATA2 gene mutations were identiﬁed in AML patients and in
three different familial syndromes characterized by predisposi-
tion to myelodysplastic syndrome (MDS) and AML.3–5 These
results collectively indicate that dysregulation of GATA2 might
be involved in the development and/or progression of AML.
In this study, we analyzed the biological effects of two novel
GATA2 mutations, which were identiﬁed in adult de novo AML
patients.2. Materials and methods
The diagnosis of AML was based on the morphology, histo-
pathology, the expression of leukocyte differentiation antigens: þ81 52 744 2157.
oi).
Y-NC-ND license.and/or the French–American–British (FAB) classiﬁcation. GATA2
mutation was screened in 96 newly diagnosed de novo AML adult
patients. Informed consent was obtained from all patients to use
their samples for banking and molecular analysis, and approval
was obtained from the ethics committee of Nagoya University
School of Medicine.
The full-length human wild-type (Wt)- and mutated (Mt)-
GATA2 cDNAs were ampliﬁed from Wt- or Mt-GATA2-expressing
leukemia cells, respectively. C-terminally Myc-tagged GATA2
cDNAs were cloned into pcDNA3.1 vector, and electrophoretic
mobility shift assay (EMSA) and luciferase assay were performed
as previously reported.6
C-terminally Myc-tagged Wt- and mutant-GATA2 cDNAs
cloned in the pMX-IP vector were transduced into murine
IL3-dependent myeloid progenitor cell line 32D cells as pre-
viously described.7 Stable Wt- and mutant-GATA2-expressing
32D cells were subjected to immunoﬂuorescence, proliferation
and differentiation analyses.
Wt- and mutant-GATA2-expressed 32D cells were suspended
in RPMI1640 medium containing 10% FCS with an increasing
concentration of murine IL3 (R&D Systems), and 2104 cells per
well were seeded in 96-well culture plates. Cell viability was
measured using the CellTiter96 Proliferation Assay (Promega). For
the induction of myeloid differentiation, Wt- and mutant-GATA2-
expressed 32D cells were cultured in RPMI1640 medium contain-
ing 10% FCS and 30 ng/ml recombinant G-CSF (Kyowa-Kirin,
Tokyo, Japan) without IL3.
Luciferase assay and cell proliferation and differentiation
analyses were performed three times independently. Differences
in continuous variables were analyzed with unpaired t test for the
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ware Inc., La Jolla, CA). For all analyses, the P values were two-
tailed, and a P valueo0.05 was considered signiﬁcant.3. Results
We identiﬁed two GATA2 genemutations. Onemutation (p.R308P-
GATA2) was a p.Arg308Pro substitution within the N-terminal
zinc ﬁnger (ZF)-1 domain in a FAB M6 patient (Fig. 1A and B). The
other mutation (p.A350_N351ins8-GATA2) was a 24-nucleotide
insertion resulting in an eight-amino-acid insertion between
A350 and N351 residues within the C-terminal ZF-2 domain
in a FAB M1 patient. This insertion mutation consisted of a one
nucleotide insertion and a 23-nucleotide corresponding to
N337-R344 residues duplication (Fig. 1A and C). In both patients,
each GATA2mutation was heterozygous. Unfortunately, we could not
analyze germ-line sequence of both patients because of the lack of
appropriate material. Therefore, we could not completely determine
whether identiﬁed mutations were somatic or germ-line mutations.
Both patients revealed normal karyotype and no mutation in FLT3,
KIT, NRAS, TP53, NPM1, CEBPA, RUNX1, MLL-PTD and IDH1/2 genes.
The expression ratios of Wt- and Mt-GATA2 transcripts of AML
cells harboring the p.A350_N351ins8 mutation were semi-
quantitatively examined using a gene scanning system with
ﬂuorescent-labeled PCR product. Although the p.A350_N351ins8
mutation was heterozygous, little expression of Wt-GATA tran-
script was observed in the primary AML cells (Fig. 1D).
We transiently expressed Wt- and mutant-GATA2 in 293T cells,
and nuclear lysates were extracted 48 h later. In EMSA using an
oligonucleotide containing GATA recognition sites, DNA-bindingFig. 1. GATA2 mutations identiﬁed in AML. (A) Two novel GATA2 mutations that were id
indicated by ZF-1 and ZF-2. (B) The sequence diagram of p.R308P mutation. The uppe
cloning procedure, respectively. (C) The sequence diagram of p.A350_N351ins8 mutatio
result after cloning procedure, respectively. (D) Expression ratio of Wt- and p.A350_
transcript was observed in the primary AML cells.activity of p.A350_N351ins8-GATA2 was reduced to about 40% of
that of Wt-GATA2, although that of p.R308P-GATA2 was almost the
same as that of Wt-GATA2 (Fig. 2A). Consistent with the DNA-
binding activity, the transcriptional activity of p.A350_N351ins8-
GATA2 was signiﬁcantly lower than that of Wt-GATA2 (P¼0.006),
while that of p.R308P-GATA2 was not affected (P¼0.11) (Fig. 2B).
Upon co-expression of Wt-GATA2 with p.A350_N351ins8-GATA2 at
a 1:1 ratio, the transcriptional activity of Wt-GATA2 was not affected
by p.A350_N351ins8-GATA, indicating that p.A350_N351ins8-GATA2
did not have a dominant-negative effect over Wt-GATA2 (Fig. 2C).
We established Wt- and two Mt- (p.R308P and p.A350_
N351ins8)-GATA2-expressing 32D cells to analyze the cellular
effects of Mt-GATA2 (Fig. 3A). Immunoﬂuorescence analysis
revealed that Mt-GATA2 showed similar localization in the
nucleus as Wt-GATA2 (Fig. 3B). Both Wt- and mutant-GATA2-
expressing 32D cells did not show autonomous proliferation
without the presence of IL3. Furthermore, there was no difference
of proliferation abilities at lower concentrations of IL3 between
them, indicating that mutant GATA2 did not provide a growth
advantage (Fig. 3C). Since mutant GATA2 did not affect the
proliferation ability, we examined the G-CSF-mediated granulocy-
tic differentiation in Wt- and Mt-GATA2-expressing 32D cells.
Mock- and Wt-GATA2-expressing 32D cells were differentiated to
mature neutrophils in the culture with G-CSF for 10 days, while
Wt-GATA2 overexpression moderately impaired the granulocytic
differentiation. In p.R308P-GATA2-expressing 32D cells, mature
neutrophil counts and promyelocyte to neutrophil counts were
signiﬁcantly lower than those of Wt-GATA2-expressing 32D cells
after the 10-day culture (P¼0.020 and P¼0.003, respectively),
while promyelocyte to neutrophil counts were the same after the
14-day culture. However, in p.A350_N351ins8-GATA2-expressingentiﬁed are shown in the domain structure of GATA2. Two zinc ﬁnger domains are
r and lower panels show the direct-sequence result and the sequence result after
n. The upper and lower panels show the direct-sequence result and the sequence
N351ins8-GATA2 transcripts of primary AML cells. Little expression of Wt-GATA
Fig. 2. DNA-binding and transcriptional activities of mutant GATA2. (A) The DNA-binding activities of Wt- and Mt-GATA2 were evaluated by EMSA using an
oligonucleotide containing GATA recognition sites. Wt-GATA2 showed the GATA2-DNA complex band (lanes 1 and 5). This band was competed by a 200-fold excess of the
unlabeled oligonucleotide (lane 2), and was super-shifted by the addition of anti-GATA2 antibody (lane 4), but not control IgG (lane 3). DNA-binding activity of
p.A350_N351ins8-GATA2 was reduced to about 40% of that of Wt-GATA2 (lane 6). In contrast, p.R308P-GATA2 showed almost the same DNA-binding activity as Wt-GATA2
(lane 7). Lower panel shows expression levels of Wt- and Mt-GATA2 proteins in 293 T cells. (B) Transcription activities of Wt- and Mt-GATA2 were evaluated by luciferase
reporter assay. 293 T cells were transfected with Wt- or Mt-GATA2 cloned pcDNA3.1 vectors together with a luciferase reporter plasmid containing eight GATA consensus
motifs. The transcription activity of p.A350_N351ins8-GATA2 was signiﬁcantly lower than that of Wt-GATA2 (P¼0.006), while that of p.R308P-GATA2 was not affected.
Mean 7SEM of three independent analyses are shown. (C) Upon co-expression of Wt-GATA2 with p.A350_N351ins8-GATA2 at a 1:1 ratio, the transcriptional activity of
Wt-GATA2 was not affected by p.A350_N351ins8-GATA2, indicating that p.A350_N351ins8-GATA2 did not have a dominant-negative effect over Wt-GATA2. Mean7SEM
of three independent analyses are shown.
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phil counts were signiﬁcantly lower than those of Wt-GATA2-
expressing 32D cells both after the 10-day and the 14-day cultures
(P¼0.016 and P¼0.0005 after 10 days, and P¼0.009 and P¼0.007
after 14 days, respectively), indicating that p.A350_N351ins8-
GATA2 impaired the G-CSF-mediated granulocytic differentiation
(Fig. 4A and B). These morphological results were conﬁrmed by
the surface expression of CD11b after G-CSF stimulation (Fig. 4C).
CD11b expression levels of p.R308P-GATA2-expressing 32D cells
were the same as Wt-GATA2-expressing 32D cells, while that of
p.A350_N351ins8-GATA2-expressing 32D cells was signiﬁcantly
lower than those of Wt-GATA2-expressing 32D cells on day 14
(P¼0.04).4. Discussion
In this study, we identiﬁed two novel GATA2 gene mutations
(p.R308P in the ZF-1 domain and p.A350_N351ins8 in the ZF-2domain) in adult de novo AML patients. Most mutations in the ZF-
2 domain of the GATA2 gene are reportedly missense mutations.8
Although three types of in-frame deletion mutations were
reported, p.A350_N351ins8 mutation was ﬁrstly identiﬁed as an
in-frame insertion mutation in the ZF-2 domain. L359V mutation,
which was recurrently identiﬁed in CML-BC, increased transacti-
vation activity and inhibited myelomonocytic differentiation and
proliferation.2 In contrast, T354M and T355del mutations, which
were identiﬁed in families with hereditary MDS/AML, dominant-
negatively reduced transactivation activity over Wt-GATA2.3
However, it is notable that T354M-GATA2 inhibited the all-trans
retinoic acid (ATRA)-induced granulocytic differentiation of HL-60
cells, but T355del-GATA2 did not. Consistent with the T354M
mutation, p.A350_N351ins8 mutation reduced DNA-binding and
transcriptional activities and impaired G-CSF-induced granulocy-
tic differentiation of 32D cells. However, in contrast to T354M-
GATA2, p.A350_N351ins8-GATA2 did not show a dominant-
negative effect over Wt-GATA2 by transcriptional assay. Since
p.A350_N351ins8 mutation was heterozygous in the clinical
Fig. 3. Establishment of Wt- and Mt-GATA2-expressing 32D cells. (A) Stable expression of GATA2 protein in each cell line was conﬁrmed by Western blotting using anti-
Myc (upper panel) and anti-GATA2 (lower panel) antibodies. Of note is that no expression of endogenous GATA2 was observed in 32D cells. White arrowhead indicates
non-speciﬁc band. (B) Immunoﬂuorescence analysis showed the same localization of Wt- and Mt-GATA2. C. Ratio of cell viability of each GATA2-expressing 32D cell to
mock-32D cells after 72-h culture at variable concentrations of IL3 is presented. Cell viability was measured using the CellTiter96 Proliferation Assay (Promega).
Mean7SEM of three independent analyses are shown. There was no signiﬁcant difference of proliferation abilities between Wt- and Mt-GATA2-expressing 32D cells.
Fig. 4. G-CSF-induced granulocytic differentiation. (A) Granulocytic differentiation of G-CSF-treated 32D cells was morphologically determined. One hundred cells were
counted in each experiment. Mean7SEM of three independent analyses are shown. Mature neutrophil counts (left panel) and promyelocyte to neutrophil counts (right
panel) on Day 10 and Day 14 were compared with Wt-GATA2-expressing 32D cells. (B) Morphological features of Wt- and Mt-GATA2-expressing 32D cells are shown.
(C) The relative MFI level of CD11b to isotype after the G-CSF treatment in Mt-GATA2-expressing 32D cells were compared with Wt-GATA2-expressing 32D cells.
Mean7SEM of three independent analyses are shown. nPo0.05, nnPo0.01, nnnPo0.001.
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involved in leukemogenesis, particularly in the impairment of
granulocytic differentiation. In 32D cells, endogenous GATA2
expression was very faint by western blot and immunohisto-
chemical analyses. Furthermore, Wt-GATA2 transcript was
expressed little in the primary AML cells harboring
p.A350_N351ins8-GATA2 mutation. These results suggested that
p.A350_N351ins8-GATA2 might act as a loss of function of GATA2
in the absence of Wt-GATA2, resulting in the impairment of
granulocytic differentiation.
Recently, several kinds of missense mutations within the ZF-1
domain were reported in AML.5 Although transcriptional activ-
ities of GATA2 ZF-1 mutants were different among the mutation
types, all of them reduced the capacity to enhance CEBPA-
dependent activation of transcription.5 p.R308P-GATA2 did not
show signiﬁcant reduction of DNA-binding and transcriptional
activities, while p.R308P-GATA2-expressing 32D cells revealed
the delay of G-CSF-induced granulocytic differentiation, suggest-
ing a possible effect on maturation machinery through the
reduction of CEBPA-dependent transcriptional activity.
In addition, further study is required to evaluate whether
identiﬁed mutations inﬂuence post-translational modiﬁcations
because they are important mechanism of transcription factors
for regulating normal and leukemic hematopoiesis.6,9–11Authors’ contributions
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